摘要
背景:不同厂家生产的人工合成人淀粉样蛋白-β (1-42) (Aβ42)肽作为最基本的合成材料已得到广泛应用。它们的聚集能力对Aβ42生理病理研究的可靠性、重复性和可比性至关重要。然而,它还没有被评估和比较。 目的:分析5种市售Aβ42肽聚合能力的一致性。 方法:用HFIP预处理以A、B、C、D、E为代表的5 Aβ42肽。将预处理后的Aβ42肽溶解在硫黄素T (ThT)溶液中,通过聚合动力学试验监测其30 h的聚合动力学。同时,预处理后的肽在磷酸盐缓冲盐水中聚集。聚合12 h后,分别采用ThT荧光、远紫外圆二色(CD)、SDS-PAGE、western blot和透射电镜(TEM)等方法进行检测。聚集8 h和12 h后,使用Cell Counting Kit-8进一步评价其对SH-SY5Y细胞的细胞毒性。 结果:在聚集动力学中,肽A、C、E呈低水平曲线,肽B、D呈典型的s型动力学曲线。在CD测定中,肽B和D的聚集物呈现较高的CD负峰,高度分别为-8.09 mdeg和-14.37 mdeg,而肽A、C和E的高度分别为-1.04、-3.55和-3.88。ThT检测中,B肽和D肽聚集体的相对荧光强度分别为7.79和8.82,高于A肽、C肽和E肽的1.19、1.71和2.70。在SDS-PAGE中,所有聚集体包含单体和11个聚合物。此外,肽B-E从二聚体到三聚体呈梯形分布,肽a聚集到二聚体。通过western blot检测,单体的条带仍然存在于所有的聚集体中。此外,肽B和D呈二聚体和三聚体,肽A和C只呈二聚体,肽E呈强三聚体。透射电镜下,仅在肽B中可以观察到原纤维,而在其他肽中则形成大量的球状聚集物。此外,肽B、D和E在聚集8 h后具有较高的细胞毒性,而肽A、B和D在聚集12 h后具有较高的细胞毒性。 结论:市售Aβ42肽在聚集能力上存在明显差异,应引起Aβ42相关基础研究领域的足够重视。不同测定方法对聚集能力的评价存在一定的差异,建立合理、统一的测定策略已迫在眉睫。
关键词: 阿尔茨海默病,Aβ42,聚集,细胞毒性,测量,差异。
Current Alzheimer Research
Title:In vitro Aggregation Ability of Five Commercially Available Aβ42 peptide
Volume: 18 Issue: 9
关键词: 阿尔茨海默病,Aβ42,聚集,细胞毒性,测量,差异。
摘要:
Background: As the most basic material, synthetic human Amyloid-β (1-42) (Aβ42) peptide from different manufacturers have been widely used. Their aggregation ability is vital to the reliability, repeatability and comparability of studies on Aβ42 physiology and pathology. However, it has not been evaluated and compared.
Objective: To analyze the consistency of the aggregation ability of 5 commercially available Aβ42 peptide.
Methods: 5 Aβ42 peptide represented as A, B, C, D and E were pretreated by HFIP. The pretreated Aβ42 peptide were dissolved in Thioflavin T (ThT) solution, and their aggregation kinetics was monitored for 30 h with the aggregation kinetics test. Meanwhile, the pretreated peptide were aggregated in phosphate buffered saline. After aggregated for 12 h, they were detected by methods of ThT fluorescence, far-UV circular dichroism (CD), SDS-PAGE, western blot, and transmission electron microscopy (TEM), respectively. After aggregation for 8 h and 12 h, their cytotoxicity to SH-SY5Y cells was further evaluated using Cell Counting Kit-8.
Results: For aggregation kinetics, peptide A, C and E remained low level curves, while peptide B and D presented typical sigmoidal kinetics curves. In CD measurement, the aggregates of peptide B and D showed relatively high negative CD peaks with the height of -8.09 mdeg and -14.37 mdeg, while the height of peptide A, C and E was -1.04, -3.55, and -3.88. In ThT assay, relative fluorescence intensity of the aggregates of peptide B and D were 7.79 and 8.82, higher than 1.19, 1.71, and 2.70 of peptide A, C and E, respectively. In SDS-PAGE, all aggregates contained monomers and eleven polymers. Moreover, peptide B-E presented a trapezoidal distribution from dimers to trimers, and peptide A aggregated to dimers. By western blot, the bands of monomers remained in all aggregates. Furthermore, peptide B and D aggregated to dimers and trimers, peptide A and C only aggregated to dimers, and peptide E showed a strong band of trimers. By TEM, protofibrils were observed only in peptide B, while substantial spherical aggregates were formed in other peptide. Additionally, peptide B, D and E exhibited higher cytotoxicity after aggregated for 8 h, whereas peptide A, B and D presented relatively high cytotoxicity after 12-hour aggregation.
Conclusion: Commercially available Aβ42 peptide showed obvious differences in aggregation ability, which should arouse enough attention in the field of basic study related to Aβ42. The aggregation ability evaluation with the various assay methods has some discrepancies, and it is highly urgent to establish a reasonable and uniform measurement strategy.
Export Options
About this article
Cite this article as:
In vitro Aggregation Ability of Five Commercially Available Aβ42 peptide, Current Alzheimer Research 2021; 18 (9) . https://dx.doi.org/10.2174/1567205018666211124105844
DOI https://dx.doi.org/10.2174/1567205018666211124105844 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements